Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login


The Cancer Letter Inc.
PO Box 9905
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Jun 2, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Non-Small Cell Lung Cancer

Alecensa Reduces Death Risk by 66 Percent in Phase III Trial


Results from a pre-specified interim analysis from the phase III J-ALEX study found that Alecensa (alectinib) reduced the risk of disease worsening or death by 66 percent compared to (Xalkori) crizotinib in Japanese people with advanced or recurrent ALK-positive non-small cell lung cancer (HR=0.34, 99% CI: 0.17-0.70, p<0.0001) who had not received prior treatment with an ALK inhibitor.

Median PFS was not reached in people who received Alecensa (95% CI: 20.3 months-not reached) versus 10.2 months median PFS (95% CI: 8.2-12.0) in people who received Xalkori.

“This is the first investigational study to show Alecensa helped people live longer without their disease getting worse compared to crizotinib,” said Sandra Horning, chief medical officer and head of Global Product Development at Genentech, the study’s sponsor.

To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.